NM_138396.6:c.61G>T

Variant summary

Our verdict is Likely benign. The variant received -2 ACMG points: 2P and 4B. PM2BP4_Strong

The NM_138396.6(MARCHF9):​c.61G>T​(p.Gly21Trp) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000015 in 1,399,618 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 13/22 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).

Frequency

Genomes: 𝑓 0.000013 ( 0 hom., cov: 29)
Exomes 𝑓: 0.000015 ( 0 hom. )

Consequence

MARCHF9
NM_138396.6 missense

Scores

1
3
15

Clinical Significance

Uncertain significance criteria provided, single submitter U:1

Conservation

PhyloP100: 0.666

Publications

0 publications found
Variant links:
Genes affected
MARCHF9 (HGNC:25139): (membrane associated ring-CH-type finger 9) MARCH9 is a member of the MARCH family of membrane-bound E3 ubiquitin ligases (EC 6.3.2.19). MARCH enzymes add ubiquitin (see MIM 191339) to target lysines in substrate proteins, thereby signaling their vesicular transport between membrane compartments. MARCH9 induces internalization of several membrane glycoproteins and directs them to the endosomal compartment (Bartee et al., 2004 [PubMed 14722266]; Hoer et al., 2007 [PubMed 17174307]).[supplied by OMIM, Apr 2010]
CDK4 (HGNC:1773): (cyclin dependent kinase 4) The protein encoded by this gene is a member of the Ser/Thr protein kinase family. This protein is highly similar to the gene products of S. cerevisiae cdc28 and S. pombe cdc2. It is a catalytic subunit of the protein kinase complex that is important for cell cycle G1 phase progression. The activity of this kinase is restricted to the G1-S phase, which is controlled by the regulatory subunits D-type cyclins and CDK inhibitor p16(INK4a). This kinase was shown to be responsible for the phosphorylation of retinoblastoma gene product (Rb). Mutations in this gene as well as in its related proteins including D-type cyclins, p16(INK4a) and Rb were all found to be associated with tumorigenesis of a variety of cancers. Multiple polyadenylation sites of this gene have been reported. [provided by RefSeq, Jul 2008]
CDK4 Gene-Disease associations (from GenCC):
  • melanoma, cutaneous malignant, susceptibility to, 3
    Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Ambry Genetics, G2P, Labcorp Genetics (formerly Invitae), ClinGen
  • malignant pancreatic neoplasm
    Inheritance: AD Classification: MODERATE Submitted by: Genomics England PanelApp

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Likely_benign. The variant received -2 ACMG points.

PM2
Very rare variant in population databases, with high coverage;
BP4
Computational evidence support a benign effect (MetaRNN=0.025394231).

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
MARCHF9NM_138396.6 linkc.61G>T p.Gly21Trp missense_variant Exon 1 of 4 ENST00000266643.6 NP_612405.2
MARCHF9XM_047429894.1 linkc.61G>T p.Gly21Trp missense_variant Exon 1 of 3 XP_047285850.1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
MARCHF9ENST00000266643.6 linkc.61G>T p.Gly21Trp missense_variant Exon 1 of 4 1 NM_138396.6 ENSP00000266643.5 Q86YJ5-1
CDK4ENST00000552862.1 linkc.-20+343C>A intron_variant Intron 1 of 2 3 ENSP00000446763.1 F8W1L8
MARCHF9ENST00000552279.1 linkn.-139G>T upstream_gene_variant 2

Frequencies

GnomAD3 genomes
AF:
0.0000133
AC:
2
AN:
150628
Hom.:
0
Cov.:
29
show subpopulations
Gnomad AFR
AF:
0.00
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.000290
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.0000149
Gnomad OTH
AF:
0.00
GnomAD2 exomes
AF:
0.0000931
AC:
5
AN:
53734
AF XY:
0.0000952
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.000782
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.0000531
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.0000152
AC:
19
AN:
1248990
Hom.:
0
Cov.:
31
AF XY:
0.0000163
AC XY:
10
AN XY:
615060
show subpopulations
African (AFR)
AF:
0.00
AC:
0
AN:
25284
American (AMR)
AF:
0.00
AC:
0
AN:
19830
Ashkenazi Jewish (ASJ)
AF:
0.000679
AC:
14
AN:
20612
East Asian (EAS)
AF:
0.00
AC:
0
AN:
27224
South Asian (SAS)
AF:
0.0000319
AC:
2
AN:
62612
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
32992
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
3530
European-Non Finnish (NFE)
AF:
0.00000199
AC:
2
AN:
1006556
Other (OTH)
AF:
0.0000199
AC:
1
AN:
50350
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.512
Heterozygous variant carriers
0
2
3
5
6
8
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0000133
AC:
2
AN:
150628
Hom.:
0
Cov.:
29
AF XY:
0.00
AC XY:
0
AN XY:
73432
show subpopulations
African (AFR)
AF:
0.00
AC:
0
AN:
41210
American (AMR)
AF:
0.00
AC:
0
AN:
15186
Ashkenazi Jewish (ASJ)
AF:
0.000290
AC:
1
AN:
3444
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5084
South Asian (SAS)
AF:
0.00
AC:
0
AN:
4780
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10416
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
308
European-Non Finnish (NFE)
AF:
0.0000149
AC:
1
AN:
67222
Other (OTH)
AF:
0.00
AC:
0
AN:
2070
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.450
Heterozygous variant carriers
0
0
1
1
2
2
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Alfa
AF:
0.00
Hom.:
0
Bravo
AF:
0.0000189
ExAC
AF:
0.0000613
AC:
3

ClinVar

Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link

Submissions by phenotype

not specified Uncertain:1
May 17, 2025
Ambry Genetics
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The c.61G>T (p.G21W) alteration is located in exon 1 (coding exon 1) of the MARCH9 gene. This alteration results from a G to T substitution at nucleotide position 61, causing the glycine (G) at amino acid position 21 to be replaced by a tryptophan (W). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.23
BayesDel_addAF
Benign
-0.34
T
BayesDel_noAF
Benign
-0.58
CADD
Uncertain
24
DANN
Uncertain
0.98
DEOGEN2
Benign
0.023
T
Eigen
Benign
-0.34
Eigen_PC
Benign
-0.40
FATHMM_MKL
Benign
0.024
N
LIST_S2
Benign
0.54
T
M_CAP
Benign
0.084
D
MetaRNN
Benign
0.025
T
MetaSVM
Benign
-1.0
T
MutationAssessor
Benign
0.0
N
PhyloP100
0.67
PrimateAI
Pathogenic
0.88
D
PROVEAN
Benign
-0.99
N
REVEL
Benign
0.055
Sift
Uncertain
0.019
D
Sift4G
Uncertain
0.030
D
Polyphen
0.96
D
Vest4
0.23
MutPred
0.39
Loss of disorder (P = 8e-04);
MVP
0.21
MPC
2.3
ClinPred
0.19
T
GERP RS
2.4
PromoterAI
0.042
Neutral
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.1
Varity_R
0.16
gMVP
0.27
Mutation Taster
=89/11
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs749926321; hg19: chr12-58149372; API